The case for assessing cannabidiol in epilepsy
Summary Intractable epilepsies have an extraordinary impact on cognitive and behavioral function and quality of life, and the treatment of seizures represents a challenge and a unique opportunity. Over the past few years, considerable attention has focused on cannabidiol (CBD), the major nonpsychotr...
Gespeichert in:
| Veröffentlicht in: | Epilepsia (Copenhagen) 2014-06, Vol.55 (6), p.787-790 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 790 |
|---|---|
| container_issue | 6 |
| container_start_page | 787 |
| container_title | Epilepsia (Copenhagen) |
| container_volume | 55 |
| creator | Cilio, Maria Roberta Thiele, Elizabeth A. Devinsky, Orrin |
| description | Summary
Intractable epilepsies have an extraordinary impact on cognitive and behavioral function and quality of life, and the treatment of seizures represents a challenge and a unique opportunity. Over the past few years, considerable attention has focused on cannabidiol (CBD), the major nonpsychotropic compound of Cannabis sativa. Basic research studies have provided strong evidence for safety and anticonvulsant properties of CBD. However, the lack of pure, pharmacologically active compounds and legal restrictions have prevented clinical research and confined data on efficacy and safety to anecdotal reports. Pure CBD appears to be an ideal candidate among phytocannabinoids as a therapy for treatment‐resistant epilepsy. A first step in this direction is to systematically investigate the safety, pharmacokinetics, and interactions of CBD with other antiepileptic drugs and obtain an initial signal regarding efficacy at different dosages. These data can then be used to plan double‐blinded placebo‐controlled efficacy trials.
A PowerPoint slide summarizing this article is available for download in the Supporting Information section here. |
| doi_str_mv | 10.1111/epi.12635 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1544003239</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1535631629</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4875-69b077e90712bc60f50370aa60c8ff04e238105ac71d288a5d945ac9b6c8a3ee3</originalsourceid><addsrcrecordid>eNqN0E9LwzAYBvAgipvTg19ACl700O1N0vzpUcbUwUAP8xzS9K12dO1sLLJvb7ZOD4JgLiHhx5M3DyGXFMY0rAluyjFlkosjMqSC6ZhSqY7JEIDyOBUaBuTM-xUAKKn4KRmwRIsk4cmQjJdvGDnrMSqaNrLeo_dl_Rqu6tpmZV42VVTWUXihwo3fnpOTwlYeLw77iLzcz5bTx3jx9DCf3i1il2glYplmoBSmoCjLnIRCAFdgrQSniwISZFxTENYpmjOtrcjTJJzSTDptOSIfkZs-d9M27x36D7MuvcOqsjU2nTc0jA_AGU__QbmQnEq2o9e_6Krp2jp8ZK9ASskhqNteubbxvsXCbNpybdutoWB2fZvQhtn3HezVIbHL1pj_yO-CA5j04DMUuP07ycye533kF46Lhik</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1535066630</pqid></control><display><type>article</type><title>The case for assessing cannabidiol in epilepsy</title><source>Wiley-Blackwell Journals</source><source>MEDLINE</source><source>Wiley Free Archive</source><source>IngentaConnect Open Access</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Cilio, Maria Roberta ; Thiele, Elizabeth A. ; Devinsky, Orrin</creator><creatorcontrib>Cilio, Maria Roberta ; Thiele, Elizabeth A. ; Devinsky, Orrin</creatorcontrib><description>Summary
Intractable epilepsies have an extraordinary impact on cognitive and behavioral function and quality of life, and the treatment of seizures represents a challenge and a unique opportunity. Over the past few years, considerable attention has focused on cannabidiol (CBD), the major nonpsychotropic compound of Cannabis sativa. Basic research studies have provided strong evidence for safety and anticonvulsant properties of CBD. However, the lack of pure, pharmacologically active compounds and legal restrictions have prevented clinical research and confined data on efficacy and safety to anecdotal reports. Pure CBD appears to be an ideal candidate among phytocannabinoids as a therapy for treatment‐resistant epilepsy. A first step in this direction is to systematically investigate the safety, pharmacokinetics, and interactions of CBD with other antiepileptic drugs and obtain an initial signal regarding efficacy at different dosages. These data can then be used to plan double‐blinded placebo‐controlled efficacy trials.
A PowerPoint slide summarizing this article is available for download in the Supporting Information section here.</description><identifier>ISSN: 0013-9580</identifier><identifier>EISSN: 1528-1167</identifier><identifier>DOI: 10.1111/epi.12635</identifier><identifier>PMID: 24854434</identifier><identifier>CODEN: EPILAK</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Anticonvulsants - adverse effects ; Anticonvulsants - therapeutic use ; Cannabidiol ; Cannabidiol - adverse effects ; Cannabidiol - therapeutic use ; Cannabis sativa ; Childhood ; Epilepsy ; Epilepsy - drug therapy ; Humans ; Phytotherapy ; Plant Extracts - therapeutic use ; Randomized Controlled Trials as Topic ; Treatment Outcome</subject><ispartof>Epilepsia (Copenhagen), 2014-06, Vol.55 (6), p.787-790</ispartof><rights>Wiley Periodicals, Inc. © 2014 International League Against Epilepsy</rights><rights>Wiley Periodicals, Inc. © 2014 International League Against Epilepsy.</rights><rights>Copyright © 2014 International League Against Epilepsy</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4875-69b077e90712bc60f50370aa60c8ff04e238105ac71d288a5d945ac9b6c8a3ee3</citedby><cites>FETCH-LOGICAL-c4875-69b077e90712bc60f50370aa60c8ff04e238105ac71d288a5d945ac9b6c8a3ee3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fepi.12635$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fepi.12635$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24854434$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cilio, Maria Roberta</creatorcontrib><creatorcontrib>Thiele, Elizabeth A.</creatorcontrib><creatorcontrib>Devinsky, Orrin</creatorcontrib><title>The case for assessing cannabidiol in epilepsy</title><title>Epilepsia (Copenhagen)</title><addtitle>Epilepsia</addtitle><description>Summary
Intractable epilepsies have an extraordinary impact on cognitive and behavioral function and quality of life, and the treatment of seizures represents a challenge and a unique opportunity. Over the past few years, considerable attention has focused on cannabidiol (CBD), the major nonpsychotropic compound of Cannabis sativa. Basic research studies have provided strong evidence for safety and anticonvulsant properties of CBD. However, the lack of pure, pharmacologically active compounds and legal restrictions have prevented clinical research and confined data on efficacy and safety to anecdotal reports. Pure CBD appears to be an ideal candidate among phytocannabinoids as a therapy for treatment‐resistant epilepsy. A first step in this direction is to systematically investigate the safety, pharmacokinetics, and interactions of CBD with other antiepileptic drugs and obtain an initial signal regarding efficacy at different dosages. These data can then be used to plan double‐blinded placebo‐controlled efficacy trials.
A PowerPoint slide summarizing this article is available for download in the Supporting Information section here.</description><subject>Anticonvulsants - adverse effects</subject><subject>Anticonvulsants - therapeutic use</subject><subject>Cannabidiol</subject><subject>Cannabidiol - adverse effects</subject><subject>Cannabidiol - therapeutic use</subject><subject>Cannabis sativa</subject><subject>Childhood</subject><subject>Epilepsy</subject><subject>Epilepsy - drug therapy</subject><subject>Humans</subject><subject>Phytotherapy</subject><subject>Plant Extracts - therapeutic use</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Treatment Outcome</subject><issn>0013-9580</issn><issn>1528-1167</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqN0E9LwzAYBvAgipvTg19ACl700O1N0vzpUcbUwUAP8xzS9K12dO1sLLJvb7ZOD4JgLiHhx5M3DyGXFMY0rAluyjFlkosjMqSC6ZhSqY7JEIDyOBUaBuTM-xUAKKn4KRmwRIsk4cmQjJdvGDnrMSqaNrLeo_dl_Rqu6tpmZV42VVTWUXihwo3fnpOTwlYeLw77iLzcz5bTx3jx9DCf3i1il2glYplmoBSmoCjLnIRCAFdgrQSniwISZFxTENYpmjOtrcjTJJzSTDptOSIfkZs-d9M27x36D7MuvcOqsjU2nTc0jA_AGU__QbmQnEq2o9e_6Krp2jp8ZK9ASskhqNteubbxvsXCbNpybdutoWB2fZvQhtn3HezVIbHL1pj_yO-CA5j04DMUuP07ycye533kF46Lhik</recordid><startdate>201406</startdate><enddate>201406</enddate><creator>Cilio, Maria Roberta</creator><creator>Thiele, Elizabeth A.</creator><creator>Devinsky, Orrin</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>201406</creationdate><title>The case for assessing cannabidiol in epilepsy</title><author>Cilio, Maria Roberta ; Thiele, Elizabeth A. ; Devinsky, Orrin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4875-69b077e90712bc60f50370aa60c8ff04e238105ac71d288a5d945ac9b6c8a3ee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Anticonvulsants - adverse effects</topic><topic>Anticonvulsants - therapeutic use</topic><topic>Cannabidiol</topic><topic>Cannabidiol - adverse effects</topic><topic>Cannabidiol - therapeutic use</topic><topic>Cannabis sativa</topic><topic>Childhood</topic><topic>Epilepsy</topic><topic>Epilepsy - drug therapy</topic><topic>Humans</topic><topic>Phytotherapy</topic><topic>Plant Extracts - therapeutic use</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cilio, Maria Roberta</creatorcontrib><creatorcontrib>Thiele, Elizabeth A.</creatorcontrib><creatorcontrib>Devinsky, Orrin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Epilepsia (Copenhagen)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cilio, Maria Roberta</au><au>Thiele, Elizabeth A.</au><au>Devinsky, Orrin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The case for assessing cannabidiol in epilepsy</atitle><jtitle>Epilepsia (Copenhagen)</jtitle><addtitle>Epilepsia</addtitle><date>2014-06</date><risdate>2014</risdate><volume>55</volume><issue>6</issue><spage>787</spage><epage>790</epage><pages>787-790</pages><issn>0013-9580</issn><eissn>1528-1167</eissn><coden>EPILAK</coden><abstract>Summary
Intractable epilepsies have an extraordinary impact on cognitive and behavioral function and quality of life, and the treatment of seizures represents a challenge and a unique opportunity. Over the past few years, considerable attention has focused on cannabidiol (CBD), the major nonpsychotropic compound of Cannabis sativa. Basic research studies have provided strong evidence for safety and anticonvulsant properties of CBD. However, the lack of pure, pharmacologically active compounds and legal restrictions have prevented clinical research and confined data on efficacy and safety to anecdotal reports. Pure CBD appears to be an ideal candidate among phytocannabinoids as a therapy for treatment‐resistant epilepsy. A first step in this direction is to systematically investigate the safety, pharmacokinetics, and interactions of CBD with other antiepileptic drugs and obtain an initial signal regarding efficacy at different dosages. These data can then be used to plan double‐blinded placebo‐controlled efficacy trials.
A PowerPoint slide summarizing this article is available for download in the Supporting Information section here.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>24854434</pmid><doi>10.1111/epi.12635</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0013-9580 |
| ispartof | Epilepsia (Copenhagen), 2014-06, Vol.55 (6), p.787-790 |
| issn | 0013-9580 1528-1167 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1544003239 |
| source | Wiley-Blackwell Journals; MEDLINE; Wiley Free Archive; IngentaConnect Open Access; Alma/SFX Local Collection; EZB Electronic Journals Library |
| subjects | Anticonvulsants - adverse effects Anticonvulsants - therapeutic use Cannabidiol Cannabidiol - adverse effects Cannabidiol - therapeutic use Cannabis sativa Childhood Epilepsy Epilepsy - drug therapy Humans Phytotherapy Plant Extracts - therapeutic use Randomized Controlled Trials as Topic Treatment Outcome |
| title | The case for assessing cannabidiol in epilepsy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T16%3A12%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20case%20for%20assessing%20cannabidiol%20in%20epilepsy&rft.jtitle=Epilepsia%20(Copenhagen)&rft.au=Cilio,%20Maria%20Roberta&rft.date=2014-06&rft.volume=55&rft.issue=6&rft.spage=787&rft.epage=790&rft.pages=787-790&rft.issn=0013-9580&rft.eissn=1528-1167&rft.coden=EPILAK&rft_id=info:doi/10.1111/epi.12635&rft_dat=%3Cproquest_cross%3E1535631629%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1535066630&rft_id=info:pmid/24854434&rfr_iscdi=true |